Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Bharat ParenteralsBOM:541096 -3.12%74 EBITDA Margin % is 3.11% as of Mar. 2026, which is 78% below its 10-year median of 14.16. GuruFocus rates BOM:541096 with a GF Score™ of 74/100 and a GF Value™ of ₹1,158.85 (Modestly Overvalued). The stock has 8 warning signs investors should review. Among 960 Drug Manufacturers companies, Bharat Parenterals ranks worse than 62.19% on this metric.
EBITDA Margin % is calculated as EBITDA divided by its Revenue. Bharat Parenterals's EBITDA for the
three
months ended in Mar. 2026 was ₹31 Mil. Bharat Parenterals's Revenue for the
three
months ended in Mar. 2026 was ₹996 Mil. Therefore, Bharat Parenterals's EBITDA margin for the quarter that ended in Mar. 2026 was 3.11%.
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Bharat Parenterals EBITDA Margin % Related Terms
Bharat Parenterals EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for Bharat Parenterals's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Bharat Parenterals's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Bharat Parenterals EBITDA Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Bharat Parenterals's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Bharat Parenterals's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Bharat Parenterals (BOM:541096) has a EBITDA Margin % of 3.11% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Bharat Parenterals and its competitors. This is 78% below median its historical median of 14.16. Over the past decade, Bharat Parenterals' EBITDA Margin % has ranged from 4.21 to 18.74. According to the industry distribution chart, Bharat Parenterals ranks #597 out of 960 companies in the Drug Manufacturers industry, placing it in the top 62.2%.
Is Bharat Parenterals' EBITDA Margin % too high?
Bharat Parenterals' current EBITDA Margin % of 3.11% is 78% below median its 10-year median of 14.16. Over the past 10 years, this metric has ranged from a low of 4.21 to a high of 18.74. The Drug Manufacturers industry median EBITDA Margin % is 12.16. Bharat Parenterals' value of 3.11% is 74.4% below this industry median. Based on the distribution chart, Bharat Parenterals ranks #597 out of 960 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Bharat Parenterals has a GF Score™ of 74/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Bharat Parenterals' EBITDA Margin % compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Bharat Parenterals ranks #597 out of 960 companies for EBITDA Margin %. This places Bharat Parenterals in the lower half of its industry. The industry median EBITDA Margin % is 12.16. Bharat Parenterals' value of 3.11% is 74.4% below this benchmark. Historically, Bharat Parenterals' own EBITDA Margin % has ranged from 4.21 to 18.74 over the past decade. While the company's 10-year median is 14.16 vs. the industry median of 12.16, Bharat Parenterals has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Drug Manufacturers company?
The median EBITDA Margin % among Drug Manufacturers companies is 12.16, based on 960 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Bharat Parenterals's current EBITDA Margin % of 3.11% is 74.4% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Bharat Parenterals and its competitors. For the Drug Manufacturers industry, the median EBITDA Margin % is 12.16 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Bharat Parenterals's current EBITDA Margin % is 3.11%, which is 78% below median its own 10-year median of 14.16. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bharat Parenterals stock overvalued right now?
Based on GuruFocus' analysis, Bharat Parenterals (BOM:541096) is currently considered Modestly Overvalued. The stock's GF Value™ is ₹1,158.85, compared to a current price of ₹1,375.00 — trading 18.7% above its estimated fair value. The current EBITDA Margin % is 3.11%, which is 78% below median its 10-year median of 14.16 and 74.4% below the Drug Manufacturers industry median of 12.16. Bharat Parenterals' overall GF Score™ is 74/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Bharat Parenterals (BOM:541096), the current EBITDA Margin % is 3.11% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Bharat Parenterals (BOM:541096) Overvalued in 2026?
Based on GuruFocus' analysis, Bharat Parenterals stock appears to be overvalued.
The current stock price of ₹1,375.00 is trading 18.7% above its estimated GF Value™ of ₹1,158.85.
GuruFocus considers Bharat Parenterals to be Modestly Overvalued.
Key valuation signals for BOM:541096:
EBITDA Margin %: 3.11% (78% below median its 10-year median of 14.16)
GF Value™: ₹1,158.85 vs. price of ₹1,375.00 (18.7% above fair value)
Industry Position: 74.4% below the Drug Manufacturers median (#597 of 960)
No single metric tells the full story. See the BOM:541096 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Bharat Parenterals Ltd is a pharmaceutical company. It provides various products such as Capsules, Dry Syrups, Sachets, Oral Liquids, Injections, Semisolids, and others. Geographically, the group has a business presence in India and Outside India.
74GF Score
Get the complete analysis for BOM:541096
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:541096 has been successfully added to your 
